Clinical Trials Logo

NSCLC clinical trials

View clinical trials related to NSCLC.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06431685 Recruiting - NSCLC Clinical Trials

Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer

Start date: April 25, 2024
Phase: Phase 1
Study type: Interventional

This phase I study aims to investigate the safety and efficacy of whole brain low dose radiotherapy (WB-LDRT) combined with ICI and intrathecal chemotherapy for treatment of refractory meningeal metastasis of lung cancer.

NCT ID: NCT06424821 Recruiting - NSCLC Clinical Trials

Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC

LungCadX
Start date: July 4, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to investigate the efficacy, safety and tolerability of PD-1/CTLA-4 inhibitor (Cadonilimab) combination with chemotherapy as first-line treatment for PD-L1 negative advanced non small cell lung cancer patients. And also explore the potential biomarkers for predicting the efficacy of PD-1/CTLA-4 inhibitor for advanced non small cell lung cancer.

NCT ID: NCT06362369 Recruiting - Colorectal Cancer Clinical Trials

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Start date: May 20, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study near completion of the Phase 1b

NCT ID: NCT06361927 Recruiting - NSCLC Clinical Trials

A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients

Start date: May 15, 2024
Phase: Phase 2
Study type: Interventional

This study includes two cohorts, cohort A is for non-squamous NSCLC and cohort B is for squamous NSCLC.

NCT ID: NCT06343402 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

Start date: May 22, 2024
Phase: Phase 1
Study type: Interventional

A first in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-8520, a KRAS G12C (ON) inhibitor, single agent and in combination with pembrolizumab in patients with advanced non-small cell lung cancer

NCT ID: NCT06339242 Recruiting - NSCLC Clinical Trials

A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis

Start date: January 1, 2024
Phase: Phase 2
Study type: Interventional

Leptomeningeal metastasis is a fatal complication of advanced lung cancer. There is no standard treatment for leptomeningeal metastasis after third-generation EGFR-TKIs. The Furmonertinib prototype persists longer in brain tissue, and its metabolites can also penetrate the blood-brain barrier. Ommaya cystlateral ventricle chemotherapy can quickly control the progression of intracranial lesions. The aim of this study is to evaluate the LM progression-free survival (LM-PFS) of Furmonertinib combined with lateral ventricular chemotherapy in the treatment of leptomeningeal metastatic NSCLC after third-generation EGFR-TKIs resistance.

NCT ID: NCT06332300 Recruiting - NSCLC Clinical Trials

An Exploratory Clinical Study of Adebelimumab in Combination With Famitinib and Chemotherapy in Patients With NSCLC

Start date: February 1, 2024
Phase: Phase 2
Study type: Interventional

This study was a single-arm design to explore the efficacy and safety of Adebelimumab in combination with famitinib and lateral ventricular chemotherapy in patients with floppy meningeal metastases from non-squamous NSCLC who have failed EGFR-TKI therapy, and included patients with pathologically confirmed non-squamous non-small cell lung cancer.

NCT ID: NCT06332287 Recruiting - NSCLC Clinical Trials

A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal Metastasis

Start date: May 1, 2023
Phase: Phase 2
Study type: Interventional

To observe the efficacy of Trilaciclib combined with lateral ventricular chemotherapy in the treatment of non-small cell lung cancer with leptomeningeal metastasis。

NCT ID: NCT06328049 Recruiting - NSCLC Clinical Trials

A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC

Start date: August 10, 2023
Phase: Phase 2
Study type: Interventional

The aim of this study is to investigate the safety and efficacy of the prophylactic use of Trilaciclib in patients with non-small cell lung cancer (NSCLC) receiving platinum-based chemotherapy, so as to provide more evidence-based medical evidence for the optimal diagnosis and treatment strategy in this population.

NCT ID: NCT06326411 Recruiting - Melanoma Clinical Trials

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

NST-628
Start date: April 9, 2024
Phase: Phase 1
Study type: Interventional

This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.